FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management

The FDA’s approval of resmetirom (Rezdiffra) marks a significant breakthrough in treating metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, conditions linked to non-alcoholic fatty liver disease (NAFLD). MASH is a growing global health concern, and resmetirom offers a novel thera...

Full description

Saved in:
Bibliographic Details
Main Authors: Muhammad Mazhar Azam, Sameen Mukhtar, Muhammad Haris, Fatima Laique, Suhaina Amir, Mubashir Mohiuddin, Bibek Giri
Format: Article
Language:English
Published: Open Exploration 2024-12-01
Series:Exploration of Drug Science
Subjects:
metabolic dysfunction-associated steatohepatitis (mash)
non-alcoholic fatty liver disease (nafld)
resmetirom
liver
fibrosis
thyroid
Online Access:https://www.explorationpub.com/uploads/Article/A100878/100878.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items